Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS) (BIOLOPTIM-RIS)
Psoriasis Vulgaris
About this trial
This is an interventional treatment trial for Psoriasis Vulgaris focused on measuring Therapeutic drug monitoring, Psoriasis, Risankizumab
Eligibility Criteria
Inclusion Criteria: Participants must have a clinical or histological diagnosis of chronic plaque-type psoriasis Participants must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study. Exclusion Criteria: Participants who have currently a predominant nonplaque form of psoriasis Participants who are pregnant, nursing or planning a pregnancy Participants who are unable or unwilling to undergo multiple venapunctures Participants who are treated according to a different dosing schedule than standard dosing of risankizumab
Sites / Locations
- AZ Maria Middelares
- AZ Sint-Lucas
- University Hospital GhentRecruiting
- Private practice Dermatology
- University Hospital Leuven
- AZ Sint-Jan
- AZ Delta Rembert
Arms of the Study
Arm 1
Experimental
Standard of care - risankizumab
Patients will continue to receive risankizumab according to the standard dosing schedule: subcutaneous injections at weeks 0 and 4, then every 12 weeks (2x 75mg).